	5 10 15 20 25 30
bioRxiv	bioRxiv, 29, 3.1% bioRxiv 29 publications, 3.1%
Antiviral Research	Antiviral Research, 26, 2.78% Antiviral Research 26 publications, 2.78%
Viruses	Viruses, 25, 2.67% Viruses 25 publications, 2.67%
Frontiers in Immunology	Frontiers in Immunology, 11, 1.18% Frontiers in Immunology 11 publications, 1.18%
Journal of Virology	Journal of Virology, 10, 1.07% Journal of Virology 10 publications, 1.07%
Nature	Nature, 10, 1.07% Nature 10 publications, 1.07%
iScience	iScience, 10, 1.07% iScience 10 publications, 1.07%
mBio	mBio, 10, 1.07% mBio 10 publications, 1.07%
Molecules	Molecules, 9, 0.96% Molecules 9 publications, 0.96%
Frontiers in Pharmacology	Frontiers in Pharmacology, 9, 0.96% Frontiers in Pharmacology 9 publications, 0.96%
Antimicrobial Agents and Chemotherapy	Antimicrobial Agents and Chemotherapy, 9, 0.96% Antimicrobial Agents and Chemotherapy 9 publications, 0.96%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 8, 0.86% International Journal of Molecular Sciences 8 publications, 0.86%
Frontiers in Microbiology	Frontiers in Microbiology, 7, 0.75% Frontiers in Microbiology 7 publications, 0.75%
Communications Biology	Communications Biology, 7, 0.75% Communications Biology 7 publications, 0.75%
Nature Communications	Nature Communications, 7, 0.75% Nature Communications 7 publications, 0.75%
European Journal of Medicinal Chemistry	European Journal of Medicinal Chemistry, 7, 0.75% European Journal of Medicinal Chemistry 7 publications, 0.75%
Journal of Medical Virology	Journal of Medical Virology, 7, 0.75% Journal of Medical Virology 7 publications, 0.75%
ACS Pharmacology & Translational Science	ACS Pharmacology & Translational Science, 7, 0.75% ACS Pharmacology & Translational Science 7 publications, 0.75%
ACS Infectious Diseases	ACS Infectious Diseases, 7, 0.75% ACS Infectious Diseases 7 publications, 0.75%
ACS Omega	ACS Omega, 7, 0.75% ACS Omega 7 publications, 0.75%
Clinical Infectious Diseases	Clinical Infectious Diseases, 7, 0.75% Clinical Infectious Diseases 7 publications, 0.75%
Science Translational Medicine	Science Translational Medicine, 7, 0.75% Science Translational Medicine 7 publications, 0.75%
Proceedings of the National Academy of Sciences of the United States of America	Proceedings of the National Academy of Sciences of the United States of America, 7, 0.75% Proceedings of the National Academy of Sciences of the United States of America 7 publications, 0.75%
Acta Pharmaceutica Sinica B	Acta Pharmaceutica Sinica B, 6, 0.64% Acta Pharmaceutica Sinica B 6 publications, 0.64%
Journal of Medicinal Chemistry	Journal of Medicinal Chemistry, 6, 0.64% Journal of Medicinal Chemistry 6 publications, 0.64%
Journal of Clinical Medicine	Journal of Clinical Medicine, 6, 0.64% Journal of Clinical Medicine 6 publications, 0.64%
Cell Reports	Cell Reports, 6, 0.64% Cell Reports 6 publications, 0.64%
PLoS Pathogens	PLoS Pathogens, 6, 0.64% PLoS Pathogens 6 publications, 0.64%
Clinical and Translational Science	Clinical and Translational Science, 6, 0.64% Clinical and Translational Science 6 publications, 0.64%
	5 10 15 20 25 30

Publishers

	50 100 150 200 250
Elsevier	Elsevier, 202, 21.6% Elsevier 202 publications, 21.6%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 126, 13.48% Cold Spring Harbor Laboratory 126 publications, 13.48%
Springer Nature	Springer Nature, 114, 12.19% Springer Nature 114 publications, 12.19%
MDPI	MDPI, 85, 9.09% MDPI 85 publications, 9.09%
Wiley	Wiley, 71, 7.59% Wiley 71 publications, 7.59%
American Chemical Society (ACS)	American Chemical Society (ACS), 56, 5.99% American Chemical Society (ACS) 56 publications, 5.99%
American Society for Microbiology	American Society for Microbiology, 39, 4.17% American Society for Microbiology 39 publications, 4.17%
Frontiers Media S.A.	Frontiers Media S.A., 37, 3.96% Frontiers Media S.A. 37 publications, 3.96%
Taylor & Francis	Taylor & Francis, 31, 3.32% Taylor & Francis 31 publications, 3.32%
Oxford University Press	Oxford University Press, 25, 2.67% Oxford University Press 25 publications, 2.67%
Bentham Science Publishers Ltd.	Bentham Science Publishers Ltd., 15, 1.6% Bentham Science Publishers Ltd. 15 publications, 1.6%
American Association for the Advancement of Science (AAAS)	American Association for the Advancement of Science (AAAS), 13, 1.39% American Association for the Advancement of Science (AAAS) 13 publications, 1.39%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 13, 1.39% Public Library of Science (PLoS) 13 publications, 1.39%
Royal Society of Chemistry (RSC)	Royal Society of Chemistry (RSC), 11, 1.18% Royal Society of Chemistry (RSC) 11 publications, 1.18%
SAGE	SAGE, 7, 0.75% SAGE 7 publications, 0.75%
Proceedings of the National Academy of Sciences (PNAS)	Proceedings of the National Academy of Sciences (PNAS), 7, 0.75% Proceedings of the National Academy of Sciences (PNAS) 7 publications, 0.75%
Massachusetts Medical Society	Massachusetts Medical Society, 6, 0.64% Massachusetts Medical Society 6 publications, 0.64%
Mary Ann Liebert	Mary Ann Liebert, 5, 0.53% Mary Ann Liebert 5 publications, 0.53%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 5, 0.53% Ovid Technologies (Wolters Kluwer Health) 5 publications, 0.53%
eLife Sciences Publications	eLife Sciences Publications, 4, 0.43% eLife Sciences Publications 4 publications, 0.43%
Pleiades Publishing	Pleiades Publishing, 4, 0.43% Pleiades Publishing 4 publications, 0.43%
Annual Reviews	Annual Reviews, 4, 0.43% Annual Reviews 4 publications, 0.43%
American College of Physicians	American College of Physicians, 2, 0.21% American College of Physicians 2 publications, 0.21%
S. Karger AG	S. Karger AG, 2, 0.21% S. Karger AG 2 publications, 0.21%
Portland Press	Portland Press, 2, 0.21% Portland Press 2 publications, 0.21%
Spandidos Publications	Spandidos Publications, 2, 0.21% Spandidos Publications 2 publications, 0.21%
King Saud University	King Saud University, 2, 0.21% King Saud University 2 publications, 0.21%
American Society for Biochemistry and Molecular Biology	American Society for Biochemistry and Molecular Biology, 2, 0.21% American Society for Biochemistry and Molecular Biology 2 publications, 0.21%
BMJ	BMJ, 2, 0.21% BMJ 2 publications, 0.21%
	50 100 150 200 250

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

935

Cite this

GOST |

Cite this

GOST Copy

Sheahan T. P. et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice // Science Translational Medicine. 2020. Vol. 12. No. 541.

GOST all authors (up to 50) Copy

Sheahan T. P., Sims A. R., Zhou S., Graham R. L., Pruijssers A. J., Agostini M. L., Leist S. R., Schäfer A., Dinnon Iii K. H., Stevens L. J., Chappell J. D., Lu X., Hughes T. M., George A. S., Hill C. S., Montgomery S., Brown A. J., Bluemling G. R., Natchus M. G., Saindane M., Kolykhalov A. A., Painter G. R., Harcourt J. L., Tamin A., Thornburg N. J., Swanstrom R., DENISON M., Baric R. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice // Science Translational Medicine. 2020. Vol. 12. No. 541.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1126/scitranslmed.abb5883

UR - https://doi.org/10.1126/scitranslmed.abb5883

TI - An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

T2 - Science Translational Medicine

AU - Sheahan, Timothy P.

AU - Sims, Amy R.

AU - Zhou, Shuntai

AU - Graham, Rachel L

AU - Pruijssers, Andrea J

AU - Agostini, Maria L

AU - Leist, Sarah R.

AU - Schäfer, Alexandra

AU - Dinnon Iii, Kenneth H

AU - Stevens, Laura J

AU - Chappell, James D.

AU - Lu, Xiaotao

AU - Hughes, Tia M

AU - George, Amelia S

AU - Hill, Collin S

AU - Montgomery, Stephanie

AU - Brown, Ariane J

AU - Bluemling, Gregory R

AU - Natchus, Michael G

AU - Saindane, Manohar

AU - Kolykhalov, Alexander A

AU - Painter, George R.

AU - Harcourt, Jennifer L.

AU - Tamin, Azaibi

AU - Thornburg, Natalie J.

AU - Swanstrom, Ronald

AU - DENISON, MARK

AU - Baric, Ralph

PY - 2020

DA - 2020/04/29

PB - American Association for the Advancement of Science (AAAS)

IS - 541

VL - 12

PMID - 32253226

SN - 1946-6234

SN - 1946-6242

ER -

BibTex

Cite this

BibTex (up to 50 authors) Copy

@article{2020_Sheahan,

author = {Timothy P. Sheahan and Amy R. Sims and Shuntai Zhou and Rachel L Graham and Andrea J Pruijssers and Maria L Agostini and Sarah R. Leist and Alexandra Schäfer and Kenneth H Dinnon Iii and Laura J Stevens and James D. Chappell and Xiaotao Lu and Tia M Hughes and Amelia S George and Collin S Hill and Stephanie Montgomery and Ariane J Brown and Gregory R Bluemling and Michael G Natchus and Manohar Saindane and Alexander A Kolykhalov and George R. Painter and Jennifer L. Harcourt and Azaibi Tamin and Natalie J. Thornburg and Ronald Swanstrom and MARK DENISON and Ralph Baric},

title = {An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice},

journal = {Science Translational Medicine},

year = {2020},

volume = {12},

publisher = {American Association for the Advancement of Science (AAAS)},

month = {apr},

url = {https://doi.org/10.1126/scitranslmed.abb5883},

number = {541},

doi = {10.1126/scitranslmed.abb5883}

}

Publisher

American Association for the Advancement of Science (AAAS)

Journal

Science Translational Medicine

scimago Q1

wos Q1

SJR

6.722

CiteScore

27.9

Impact factor

14.6

ISSN

19466234 (Print)

19466242 (Electronic)